Thr1949

Site Information
IIEkttRtPEEGGys SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 481054
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 )
Disease tissue studied:	Alzheimer's disease ( 33 ) , breast cancer ( 7 , 22 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 7 ) , leukemia ( 34 ) , chronic myelogenous leukemia ( 34 ) , lung cancer ( 6 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 22 , 29 , 30 ) , non-small cell lung cancer ( 11 , 12 , 13 , 15 , 16 , 17 , 20 , 22 , 30 ) , non-small cell lung adenocarcinoma ( 6 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 20 ) , non-small cell large cell lung carcinoma ( 12 , 15 ) , non-small cell squamous cell lung carcinoma ( 14 ) , small-cell lung cancer ( 9 , 10 ) , pancreatic ductal adenocarcinoma ( 8 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:	'brain, cerebral cortex' ( 33 ) , 'pancreatic, ductal'-pancreas ( 8 ) , 'stem, embryonic' ( 32 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 35 ) , 293 (epithelial) ( 26 , 27 ) , A498 (renal) ( 28 ) , A549 (pulmonary) ( 11 , 18 ) , breast ( 3 , 7 ) , BT-20 (breast cell) ( 22 ) , BT-549 (breast cell) ( 22 ) , Cal-12T (pulmonary) ( 17 ) , Calu 6 (pulmonary) ( 22 ) , Calu-3 (pulmonary) ( 13 ) , DG75 (B lymphocyte) ( 25 ) , DMS153 (pulmonary) ( 16 ) , DMS53 (pulmonary) ( 10 ) , DMS79 (pulmonary) ( 9 ) , H2009 (pulmonary) ( 22 ) , H2077 (pulmonary) ( 22 ) , H2887 (pulmonary) ( 22 ) , H322M (pulmonary) ( 22 ) , HCC1359 (pulmonary) ( 22 ) , HCC15 (pulmonary) ( 14 ) , HCC1937 (breast cell) ( 22 ) , HCC2279 (pulmonary) ( 22 ) , HCC366 (pulmonary) ( 22 ) , HCC4006 (pulmonary) ( 22 ) , HCC44 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 15 , 22 ) , HCC827 (pulmonary) ( 13 , 22 ) , HeLa (cervical) ( 2 , 24 , 31 ) , HOP62 (pulmonary) ( 22 ) , K562 (erythroid) ( 21 , 34 ) , LCLC-103H (pulmonary) ( 22 ) , LOU-NH91 (squamous) ( 14 , 22 ) , lung ( 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 29 , 30 ) , MCF-7 (breast cell) ( 22 ) , MDA-MB-231 (breast cell) ( 22 ) , MDA-MB-468 (breast cell) ( 22 ) , NCI-H128 (pulmonary) ( 9 ) , NCI-H1299 (pulmonary) ( 12 ) , NCI-H1355 (pulmonary) ( 11 ) , NCI-H1395 (pulmonary) ( 22 ) , NCI-H1417 (pulmonary) ( 9 ) , NCI-H1437 (pulmonary) ( 16 , 17 ) , NCI-H1568 (pulmonary) ( 22 ) , NCI-H157 (pulmonary) ( 22 ) , NCI-H1648 (pulmonary) ( 22 ) , NCI-H1650 (pulmonary) ( 13 ) , NCI-H1666 (pulmonary) ( 17 , 22 ) , NCI-H1703 (squamous) ( 14 ) , NCI-H1734 (pulmonary) ( 12 ) , NCI-H1781 (pulmonary) ( 15 ) , NCI-H1792 (pulmonary) ( 11 ) , NCI-H1944 (pulmonary) ( 12 ) , NCI-H1975 (pulmonary) ( 13 ) , NCI-H2030 (pulmonary) ( 22 ) , NCI-H2073 (pulmonary) ( 14 , 16 ) , NCI-H209 (pulmonary) ( 9 , 16 ) , NCI-H2106 (pulmonary) ( 13 ) , NCI-H2172 (pulmonary) ( 22 ) , NCI-H2228 (pulmonary) ( 15 , 20 ) , NCI-H23 (pulmonary) ( 11 ) , NCI-H2342 (pulmonary) ( 14 ) , NCI-H2405 (pulmonary) ( 17 ) , NCI-H3122 (pulmonary) ( 15 ) , NCI-H322 (pulmonary) ( 22 ) , NCI-H358 (pulmonary) ( 12 ) , NCI-H441 (pulmonary) ( 11 ) , NCI-H446 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 12 , 22 ) , NCI-H520 (squamous) ( 22 ) , NCI-H524 (pulmonary) ( 9 ) , NCI-H526 (pulmonary) ( 10 ) , NCI-H647 (pulmonary) ( 22 ) , NCI-H661 (pulmonary) ( 15 ) , NCI-H69 (pulmonary) ( 10 ) , NCI-H82 (pulmonary) ( 10 ) , NCI-H838 (pulmonary) ( 16 ) , PC9 (pulmonary) ( 6 , 22 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:	AZD1152 ( 24 ) , EGF ( 2 ) , ZM447439 ( 24 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
5	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
6	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
19	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
20	Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
21	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
22	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
23	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
24	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
25	Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72 20562096 Curated Info
26	Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
27	Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
28	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
29	Rikova K (2010) CST Curation Set: 9768; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
30	Rikova K (2010) CST Curation Set: 9459; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
31	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
32	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
33	Xia Q, et al. (2008) Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. J Proteome Res 7, 2845-51 18510355 Curated Info
34	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
35	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info